SUSTOL

Peak

granisetron

NDASUBCUTANEOUSINJECTABLE
Approved
Aug 2016
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
13

Mechanism of Action

Serotonin 3 Receptor Antagonists

Pharmacologic Class:

Serotonin-3 Receptor Antagonist

Clinical Trials (5)

NCT05434663Phase 4Unknown

Safety Study of Repeat Doses of SUSTOL in Adults

Started Jul 2022
NCT05027646Phase 1Completed

Study to Assess Bioequivalence and Adhesion Properties Between Two Granisetron Transdermal Patches.

Started Jul 2021
134 enrolled
Healthy Volunteers
NCT04085393Phase 2Withdrawn

Granisetron Extended Release Injection (GERSC) for the Prevention of Chemotherapy-induced Nausea and Vomiting

Started Aug 2020
NCT04501211Phase 2Withdrawn

Open Label Transdermal Granisetron to Relieve Chronic Nausea and Emesis

Started Jan 2019
0
Gastroparesis
NCT02106494Phase 3Completed

A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC

Started Mar 2014